Log in
Enquire now
Qure Ventures

Qure Ventures

Qure Ventures is a venture capital and private equity firm investing in digital health companies.

OverviewStructured DataIssuesContributors

Contents

qureventures.com
Is a
Venture capital firm
Venture capital firm
Investor
Investor
Organization
Organization
Company
Company

Company attributes

Industry
Healthcare
Healthcare
Digital health
Digital health
Investment
Investment
Location
Sydney
Sydney
Herzliya
Herzliya
Pitchbook URL
pitchbook.com/profiles...183174-85
Parent Organization
OurCrowd
OurCrowd
0
Investors
OurCrowd
OurCrowd

Venture Capital Firm attributes

Invested in
CyberMDX
CyberMDX
BrainQ
BrainQ
sweetch
sweetch

Other attributes

Company Operating Status
Active

Qure Ventures is a venture capital and private equity firm investing in digital health companies that is headquartered in Jerusalem, Israel and was founded in 2012 by OurCrowd. The firms two managing partners are Dr. Yossi Bahagon and Allen Kamer. Qure Venture also has an office in Sydney, Australia.

Notable investments made by Qure Ventures include: Zebra Medical.Vision, Primo, Dario, Igentify, CybermdX, Tytocare, Sweetch, MedAware, and BrainQ.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Associated Investment Funds

Accelerator Batches

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Qure Ventures

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.